please refer attachement
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emmessar Biotech reported FY2026 revenue from operations of ₹37.08 lakh, down sharply from ₹61.09 lakh in FY2025 — a ~39% decline in core business revenue. However, total income stood at ₹240.66 lakh (down 8% from ₹261.96 lakh) due to other income of ₹203.58 lakh from rent on leasehold land. Profit after tax grew 37.8% to ₹43.59 lakh from ₹31.62 lakh, with EPS at ₹0.81 vs ₹0.61 prior year. The company operates in two segments: Healthcare (core biotech business declining) and Rent on leasehold land (stable rental income). The auditor issued an unmodified opinion confirming clean books.
Revenue decline in the core healthcare segment is a concern, but strong PAT growth and positive operating cash flow of ₹26.51 lakh provide some comfort. The stock may face pressure due to the near-40% drop in operational revenue despite the company's ability to maintain profitability through rental income.